

Peripheral Transcriptomics in Acute and Long-Term Kidney Dysfunction in SARS-CoV2 Infection

Title. Peripheral Transcriptomics in Acute and Long-Term Kidney Dysfunction in SARS-CoV2 Infection

Short Title. Transcriptomics in COVID-19 associated kidney disease

Author Block. Pushkala Jayaraman¹, Madhumitha Rajagopal², Ishan Paranjpe³, Lora Liharska⁴, Mayte Suarez-Farinas⁵, Ryan Thompson¹, Diane Marie Del Valle⁶, Noam Beckmann^{1,7}, Wonsuk Oh^{1,7}, Faris F. Gulamali^{1,7}, Justin Kauffman^{1,7}, Edgar Gonzalez-Kozlova⁴, Sergio Dellepiane², George Vasquez-Rios², Akhil Vaid^{1,7}, Joy Jiang¹, Annie Chen¹, Ankit Sakhuja^{1,7}, Steven Chen⁸, Ephraim Kenigsberg⁴, John Cijiang He², Steven G Coca², Lili Chan^{2,1,7}, Eric Schadt⁴, Miram Merad^{6,8}, Seunghee Kim-Schulze^{6,8}, Sacha Gnjatic⁸, Ephraim Tsalik⁹, Raymond Langley¹⁰, Alexander W Charney^{1,4,11}, Girish N Nadkarni^{1,2,7}

1 The Charles Bronfman Institute for Personalized Medicine (CBIPM), Icahn School of Medicine at Mount Sinai, New York, NY USA

2 Samuel Bronfman Department of Medicine The Barbara T Murphy Division of Nephrology Icahn School of Medicine at Mount Sinai, New York, NY USA

3 Department of Medicine Stanford University, Stanford, CA, USA

4 Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY USA

5 Department of Population Health Science and Policy Icahn School of Medicine at Mount Sinai, New York, NY USA

6 Department of Immunology and Immunotherapy Icahn School of Medicine at Mount Sinai, New York, NY USA

7 Division of Data Driven and Digital Medicine (D3M), Icahn School of Medicine at Mount

Peripheral Transcriptomics in Acute and Long-Term Kidney Dysfunction in SARS-CoV2 Infection

Sinai, New York, NY USA

8 The Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY USA

9 Center for Applied Genomics & Precision Medicine Division of Infectious Diseases Duke University School of Medicine Raleigh NC USA

10 Department of Pharmacology University of South Alabama Mobile AL USA

11 Department of Psychiatry Icahn School of Medicine at Mount Sinai, New York, NY USA

***Corresponding Author:**

Girish N Nadkarni, MD, MPH

Icahn School of Medicine at Mount Sinai, New York, NY, USA

girish.nadkarni@mountsinai.org

Peripheral Transcriptomics in Acute and Long-Term Kidney Dysfunction in SARS-CoV2 Infection

ABSTRACT

Background. Acute kidney injury (AKI) is common in hospitalized patients with SARS-CoV2 infection despite vaccination and leads to long-term kidney dysfunction. However, peripheral blood molecular signatures in AKI from COVID-19 and their association with long-term kidney dysfunction are yet unexplored.

Methods. In patients hospitalized with SARS-CoV2, we performed bulk RNA sequencing using peripheral blood mononuclear cells(PBMCs). We applied linear models accounting for technical and biological variability on RNA-Seq data accounting for false discovery rate (FDR) and compared functional enrichment and pathway results to a historical sepsis-AKI cohort. Finally, we evaluated the association of these signatures with long-term trends in kidney function.

Results. Of 283 patients, 106 had AKI. After adjustment for sex, age, mechanical ventilation, and chronic kidney disease (CKD), we identified 2635 significant differential gene expressions at $FDR < 0.05$. Top canonical pathways were *EIF2* signaling, oxidative phosphorylation, mTOR signaling, and Th17 signaling, indicating mitochondrial dysfunction and endoplasmic reticulum (ER) stress. Comparison with sepsis associated AKI showed considerable overlap of key pathways (48.14%). Using follow-up estimated glomerular filtration rate (eGFR) measurements from 115 patients, we identified 164/2635 (6.2%) of the significantly differentiated genes associated with overall decrease in long-term kidney function. The strongest associations were 'autophagy', 'renal impairment via fibrosis', and 'cardiac structure and function'.

Conclusions. We show that AKI in SARS-CoV2 is a multifactorial process with mitochondrial dysfunction driven by ER stress whereas long-term kidney function decline is associated with

Peripheral Transcriptomics in Acute and Long-Term Kidney Dysfunction in SARS-CoV2 Infection

cardiac structure and function and immune dysregulation. Functional overlap with sepsis-AKI also highlights common signatures, indicating generalizability in therapeutic approaches.

Peripheral Transcriptomics in Acute and Long-Term Kidney Dysfunction in SARS-CoV2 Infection

SIGNIFICANCE STATEMENT

Peripheral transcriptomic findings in acute and long-term kidney dysfunction after hospitalization for SARS-CoV2 infection are unclear. We evaluated peripheral blood molecular signatures in AKI from COVID-19 (COVID-AKI) and their association with long-term kidney dysfunction using the largest hospitalized cohort with transcriptomic data. Analysis of 283 hospitalized patients of whom 37% had AKI, highlighted the contribution of mitochondrial dysfunction driven by endoplasmic reticulum stress in the acute stages. Subsequently, long-term kidney function decline exhibits significant associations with markers of cardiac structure and function and immune mediated dysregulation. There were similar biomolecular signatures in other inflammatory states, such as sepsis. This enhances the potential for repurposing and generalizability in therapeutic approaches.

Peripheral Transcriptomics in Acute and Long-Term Kidney Dysfunction in SARS-CoV2 Infection

INTRODUCTION

Acute kidney injury (AKI) is common in hospitalized patients with SARS-CoV2 infection and the clinical syndrome of coronavirus disease-19 (COVID-19).^{1,2} During the COVID-19 pandemic in the United States, AKI incidence was highly variable.^{1,3-5} While the rates of AKI have decreased and even have overall less severity during vaccination, it is still a significant complication.^{6,7} However, the molecular pathophysiology of AKI in COVID-19 is unclear.^{2,8}

Previous studies used post-mortem histopathological samples to understand the pathophysiology of COVID-19 associated AKI.^{2,9-11} Although limited by selection bias, acute tubular injury is the most common observation across these studies. Additionally, these studies demonstrated comparable morphological, transcriptomic, and proteomic features between COVID-19 associated AKI (COVID-AKI) and sepsis associated AKI.¹² However, there have not been any studies on peripheral transcriptomics in general hospitalized populations to complement these findings.

In addition to AKI, COVID-19 is associated with long term kidney function.¹³⁻¹⁵ Decline in kidney function is a major component of post-acute sequelae of SARS-CoV2 (PASC).¹⁶ However, peripheral transcriptomics linked to long term kidney dysfunction and PASC are unknown, especially if the initial SARS-CoV2 infection required hospitalization.¹⁶

We have previously shown that acute markers for tubular injury and hemodynamic instability play a role in COVID-AKI and long-term kidney function decline using plasma proteomics.¹⁷ In this study, we aim to understand how the molecular mechanisms of immune dysfunctions in COVID-AKI are regulated via transcriptomic analysis of peripheral-blood samples, using peripheral blood mononuclear cells (PBMCs) of patients. Specifically, we sought to (1) identify canonical pathways and genes that are differentially expressed in

Peripheral Transcriptomics in Acute and Long-Term Kidney Dysfunction in SARS-CoV2 Infection

COVID-AKI, (2) understand if AKI in COVID was distinct from other inflammatory states via comparison with a pre-COVID-19 bulk-transcriptomics dataset of sepsis associated AKI, and (3) evaluate whether any identified signatures and/or pathways are associated with long-term kidney dysfunction.

Peripheral Transcriptomics in Acute and Long-Term Kidney Dysfunction in SARS-CoV2 Infection

METHODS

Patient Cohort

The detailed cohort characteristics and specimen collection procedures are previously described.¹⁸ For each COVID-19 patient, we defined cases as COVID-19 patients who developed AKI (stage 1, 2 or 3) during their admission (n=106) and controls as all other COVID-19 patients (n=177) without AKI (**Figure 1a**). We used samples acquired at the last available timepoint during the hospital course (**Figure 1b**). We excluded patients who developed AKI after the last specimen collection. If a patient had multiple AKI events during their hospitalizations, we included the sample collected after their last AKI event to avoid repeat sampling/confounding.¹⁷ The Mount Sinai Institutional Review Board approved this study¹⁹ under a regulatory approval allowing for access to patient-level data and biospecimen collection. This research was reviewed and approved by the Icahn School of Medicine at Mount Sinai Program for the Protection of Human Subjects (PPHS) under study number 20-00341. Data for the analysis including the clinical covariates are available in Synapse syn35874390.¹⁴ Access to the data and steps to process the clinical information to create the cohort are detailed on the site.¹⁴ All clinical experimentation methods pursued in this study are in adherence with the Declaration of Helsinki.

Definition of Acute Kidney Injury

We defined AKI per Kidney Disease Improving Global Outcomes (KDIGO)²⁰ criteria: an increase in serum creatinine by an absolute value of 0.3 mg/dL in a period of 48h or by at least 1.5 times the baseline creatinine (historical measurement) within a period of 7 days. For

Peripheral Transcriptomics in Acute and Long-Term Kidney Dysfunction in SARS-CoV2 Infection

patients with previous serum creatinine measurements available in the 365 days before admission, we considered the minimum value as the baseline creatinine. For patients without baseline creatinine in this period, a baseline reference value was used based on an estimated glomerular filtration rate (eGFR) of 75 ml/min per 1.73m² was implemented from the MDRD equation, as per the KDIGO AKI guidelines.^{21,22}

Sample Collection, Sequencing, and RNA-seq count data processing.

We extracted patient demographic and laboratory data from an institutional electronic health records (EHR) database^{14,19}. Further processing of the whole blood and PBMC samples, RNA sequencing, and quantification were carried out according to previously standardized protocols (**Supplementary Information**).¹⁴ We normalized the raw counts for the gene expressions using the edgeR package and log₂ transformed to log counts per million (CPM). We then normalized raw count data (58920) using the calcNormFactors function and then transformed to normalized log₂ CPM with weights computed by *voom* from the *limma* (R v4.3) package²³. We included genes with more than 1 count per million (CPM) in at least 10% of the samples (28 samples) in the analysis (n=18553).²³

Dimensionality Reduction and Linear Model Development

We performed principal component analysis (PCA) (**Supplementary Figure 1**) using *voom*-transformed normalized log₂ CPM of the genes in the input matrix using *prComp* function (R v4.0.3) to plot the top 4 principal components (PCs). We then computed canonical correlation among the technical, biological and clinical covariates using *CanCorrPairs*²⁴ from the *variancePartition* R package and visualized the associations using the *plotCorrMatrix*

Peripheral Transcriptomics in Acute and Long-Term Kidney Dysfunction in SARS-CoV2 Infection

function (**Supplementary Information**). The workflow to compute canonical correlations and visualize them was applied in a previously published workflow on samples that were part of the same biobank for a different study (**Supplementary Information**).¹⁴ Following this step, we undertook a data-driven approach to identify a series of non-redundant technical and biological covariates that accounted for a substantial fraction of unwanted variation in gene expression. We iteratively identified a covariate (biological, clinical, or technical) whose effect was the strongest observed driver of unwanted variance in the cohort. The identified variable, thus being tagged as a driver of unwanted variance, was then added to the linear model. We repeated this procedure iteratively until no further confounding variables were observed to be strong drivers of variance in the data, as shown in **Supplementary Figure 1B**. We adjusted for the selected variables in all subsequent linear modeling. The contribution of each of the covariates to the overall variance in the data was visualized by conducting a variance partition analysis using *variancePartition* R package²⁴.

Differential expression and analysis

We carried out differential expression analysis between cases and controls using *limma* (R v4.3) and adjusted the model for the following clinical covariates: presence or absence of mechanical ventilation, sex, age, and chronic kidney disease (CKD) (as documented comorbidity in the EHR). We used cell-type deconvolution using CIBERSORTX^{23,24} to estimate cell type proportions in each sample using LM22 PBMCs as reference following a previously published workflow¹⁴ and then iteratively adjusted the linear model for neutrophils, plasma cells, macrophages, and CD4+ memory activated T-cells²⁵ (**Supplementary Information**). After multiple testing correction on the p-values of the genes (Bonferroni-adjusted

Peripheral Transcriptomics in Acute and Long-Term Kidney Dysfunction in SARS-CoV2 Infection

$FDR \leq 0.05$), we plotted the statistically significant genes in a volcano plot to depict the separation between the expression of genes with increased and decreased transcription abundances through log fold change (logFC).

Comparison with Sepsis associated AKI.

To account for differences between sepsis-associated and COVID- AKI, we compared the statistically significant ($FDR < 0.05$) list of differentially expressed genes and canonical pathways enriched for these genes to a previously published dataset (including differential gene expression results, pathways and normalized gene expression) from participants with sepsis and AKI before the COVID-19 pandemic.²⁵ We downloaded expression data from GEO for project GSE67401²⁵ and obtained the associated clinical phenotypes. We performed differential expression analysis using the DESeq2²⁶ package following the protocol as described in the original manuscript²⁵ and identified differentially expressed genes ($FDR < 0.05$) between the cases and controls in the sepsis-AKI cohort. After Bonferroni adjustment, we performed a one-sided Fisher's exact test to identify enrichment and analyze overlap between the genes. We also extracted the published pathways from the manuscript²⁵ and performed an overlap analysis to identify common pathways enriched in both datasets.

Characterization of long-term kidney function using markers of AKI

We used post-discharge creatinine values measured for returning patients to compute estimated glomerular filtration rate (eGFR) values using the CKD-EPI equation.²⁷ Clinical data pertinent to returning patients within this cohort including protein measurements were extracted from the EHR starting from the day after discharge with follow-up care through

Peripheral Transcriptomics in Acute and Long-Term Kidney Dysfunction in SARS-CoV2 Infection

12/2/2021. Outpatient eGFR measurements from repeated serum creatinine measurements from patients contained at least one outpatient post-discharge eGFR measurement. We included 115 patients who returned for post-discharge clinical care in this cohort. To determine association of overall expression of markers for AKI with long-term post-discharge kidney function, we modeled the association of the differential gene signatures of AKI in COVID-19 to the overall changes in post-discharge eGFR using a mixed-effects linear regression model (`lme4`²⁸ package in R v4.0.3). We adjusted the model for baseline creatinine, number of days since RNA-seq sample was extracted, presence of AKI during hospitalization, and the individual gene expressions as the fixed effect and patient ID as random effect accounting for the correlation among eGFR values from the same individuals. We evaluated significance of the β coefficient for the expression of each of the independent gene expressions using a *t-test* with Satterthwaite degrees of freedom implemented in the *lmerTest* R package.²⁸ We adjusted p-values using the Benjamini-Hochberg procedure (FDR < 0.05).²⁹ We then plotted the post-discharge eGFR values over time for individuals clustered by gene expression tertiles (bottom 33rd percentile, middle 33rd percentile, and top 33rd percentile) for AKI cases and controls separately (**Supplementary Figure S5**).

Functional association and statistical analysis

Pathway enrichment analysis was performed for the differentially expressed genes through Ingenuity Pathway Analysis (IPA)²⁶ to uncover functional associations and causal networks enriched (Fishers exact test p-value < 0.05) for differentially expressed genes in the COVID-associated AKI cohort. IPA canonical pathway analysis also included calculated z-scores that represented activation (positive z-score) or inhibition state (negative z-score). We selected for

Peripheral Transcriptomics in Acute and Long-Term Kidney Dysfunction in SARS-CoV2 Infection

the top canonical pathways at a p-value cut-off of 0.05. Further, top regulatory genes, disease functions, and curated toxicity functions were investigated within IPA for both, up, and downregulated genes.

Peripheral Transcriptomics in Acute and Long-Term Kidney Dysfunction in SARS-CoV2 Infection

RESULTS

Description of the study population

Of 283 patients in the COVID-AKI cohort, 106 (37%) had AKI. Patients with COVID-associated AKI were on average older than those without (67 years vs 60 years, $p=0.014$) with a similar distribution of race (36% White and 21% Black versus 32% White and 24% Black patients, p -value not significant). Sequential Organ Failure Assessment (SOFA) scores³⁰ were also significantly greater in those with COVID-associated AKI compared with controls (5.7 vs 1.2, $p<0.001$). Laboratory parameters including blood urea nitrogen levels (52.2 mmol/L vs 16.9 mmol/L, $p < 0.001$), leukocyte counts ($12.8 \times 10^9/L$ vs $7.8 \times 10^9/L$, $p<0.001$), and ferritin (1650 ug/L vs 932 ug/L, $p 0.027$) were significantly higher in patients with AKI. Patients with COVID-associated AKI had a greater prevalence of atrial fibrillation (20% vs 10%, $p 0.018$), type 2 diabetes (37% vs 20%, $p<0.001$), and comorbid CKD (20% vs 5%, $p<0.001$) and were also more likely to have been on any vasopressors (52% vs 7%, $p <0.001$) during their hospitalization.

The post-discharge eGFR cohort comprised 115 with follow up data (**Table 1B**). 34 had AKI and were part of the COVID-AKI case cohort. Median age was 62 years, 50% were male and 24.3% white. 11% of the patients had CKD stage 3 or higher and 30% had type 2 diabetes. The median duration of follow-up was 162 days with a median of 4 eGFR measurements (**Table 1C**).

Differential Expression Analysis

Peripheral Transcriptomics in Acute and Long-Term Kidney Dysfunction in SARS-CoV2 Infection

Differential expression analysis yielded 2635 genes which were differentially expressed in cases: 1223 higher expression and 1412 genes with lower expression in AKI versus control (FDR<0.05) (**Figure 2A, Supplementary Table 2A & 2B**).

Functional analysis of the differentially expressed genes revealed a subset of genes involved in upstream regulation of transcription targets (regulatory genes) were also significantly differentially expressed. Master regulators, namely, *mir-21*, *KLF6*, *MEG3*, *KIT*, *PRL* and *TGFβ1* were overexpressed (~1.5x fold increase), while *IFN-gamma* (*IFNγ* or *IFN-g*), *mir-15*, *mir-19*, *CAB39L* and *EIF3E* had significantly lower levels of gene expression than controls (~0.5x fold decrease). Of the known biomarkers for AKI progression and renal tubular injury *HIF1A*, *KLF6*, *IL1-R1* and *mir-21* showed significantly increased expression (**Supplementary Table 2C**).

Functional analysis of differentially expressed genes.

Functional enrichment analysis identified several enriched pathways associated via an overlap with the expressed genes in the dataset (right-tailed Fisher's exact test P-value < 0.05, Benjamini Hochberg correction) (**Figure 3 and Supplementary Information Figure S2A-C**). 'Canonical pathways' are identified as well-characterized and hand-curated signaling and metabolic pathways that have been extracted from literature, textbooks, and the HumanCyc database, maintained in IPA. The top pathways were *EIF2* signaling/regulation of *eif4* and *p70S6K* signaling, coronavirus pathogenesis pathway, oxidative phosphorylation, mitochondrial dysfunction, and endoplasmic reticulum (ER) stress (**Figure 3A**). Pathway overrepresentation analysis also interrogated the differentially expressed genes in IPA-curated pathways (**Supplementary Information Figure S2B**). Among them, 'mitochondrial

Peripheral Transcriptomics in Acute and Long-Term Kidney Dysfunction in SARS-CoV2 Infection

dysfunction' and '*NF- κ B* signaling' had large percentages of downregulated genes, while pathways that impacted cardiac hypertrophy, increased renal damage, and *PPAR/RXR* activation had higher percentages of upregulated genes.

Comparison with sepsis associated AKI.

Of the published canonical pathways in the s-AKI dataset, more than 50% of the pathways overlapped with the enriched canonical pathways in the COVID-AKI dataset (**Supplementary Table 2.C.**). Cellular processes associated with mitochondrial dysfunction, oxidative phosphorylation, and cellular stress (see **Supplementary Fig S4**) were some of the top common pathways. Of the 630 significant differentially expressed genes generated from the s-AKI cohort, 111 of them were also found in the COVID-AKI dataset. The Fisher exact test statistical significance for enrichment of sepsis-AKI genes in COVID-AKI cohort was < 0.00001 (**Supplementary Information**).

Characterization of post-acute kidney dysfunction

COVID-19 is associated with long-term eGFR decline.^{13,15} Of the ~2619 differentially expressed genes for COVID-AKI, we also found 164 genes (**Figure 4**) were associated with overall change in eGFR (**Supplementary Table 2D & 2E**). Those with the highest ranked association (ranks determined by the strength of the association (**Figure 5**) of the gene expressions against overall rate of eGFR) are *CALCOCO2*, *SIK3*, *mir29*, *KDM8*, and *MEF2C* (**Supplementary Table 2F**). Pathway over-representation analysis in IPA revealed an enrichment for ABRA signaling pathway with MEF2C and TAGLN as key regulators in the pathway (**Supplementary Table 2G**). Significant functional and diseases associations in IPA

Peripheral Transcriptomics in Acute and Long-Term Kidney Dysfunction in SARS-CoV2 Infection

included regulation of actin cytoskeleton, cellular adhesion and proliferation, and cardiovascular system development and function (IPA Content Version: 101138820, Release Date: 2023-08-24).

Peripheral Transcriptomics in Acute and Long-Term Kidney Dysfunction in SARS-CoV2 Infection

DISCUSSION:

To our knowledge, this is the largest peripheral transcriptomics study in hospitalized COVID-19 patients who develop AKI. Our results show that COVID-AKI is associated with molecular perturbations within the regulatory markers of endoplasmic reticulum (ER) stress,³¹ tubular injury, mitochondrial dysfunction, and oxidative phosphorylation. Some pathways are also found to be common to those with sepsis-AKI including Hypoxia Signaling in the Cardiovascular System, ERK/MAPK Signaling, Unfolded protein response, and *IL-1* signaling.³²⁻³⁴ In addition, we uncover associations between a subset of these acute-phase, COVID-19 molecular markers and long-term kidney function dysfunction, including markers of autophagy, renal impairment via fibrosis, and cardiac structure/function.

We utilized peripheral blood mononuclear cells (PBMCs) as a model system to understand the underlying peripheral molecular mechanisms of AKI in COVID-19. One example of the mononuclear cell system is circulating monocytes, influenced by the cytokines or other molecular interactions to be recruited into injured tissues to differentiate into specific macrophage phenotypes.³⁵ Thus, PBMCs serve as surrogates for systemic physiological changes,^{36,37} and their bioenergetic profiles have gained substantial attention³⁸ in recent investigations of various diseases.³⁹

The *eIF2* pathway was inhibited, and *mTOR* was activated in our cohort (**Figure 3A**). These pathways have previously been implicated in AKI development both in ischemia-reperfusion and in sepsis-associated AKI. Coronaviruses induce cellular stress by disrupting cellular homeostasis and triggering ER stress^{40,41} and cellular stress induced activation of *eIF2*- α kinases and phosphorylation of the α subunit of *eIF2* to inhibit *eIF-2* signaling.⁴² Additionally, viral infection acts via the *eIF2* α pathway to cause global inhibition of translation while

Peripheral Transcriptomics in Acute and Long-Term Kidney Dysfunction in SARS-CoV2 Infection

upregulating proinflammatory cytokines.^{31,42} The *mTOR* pathway is intertwined with the activation of ER stress response via eukaryotic initiation factor (*eIF2/4* complex).^{43,44} As a viable target for therapeutic intervention, rapamycin, an inhibitor of mTOR signaling, has been shown to offer a protective effect against progression in rodent models of CKD.⁴⁵ Other *mTOR* inhibitors (everolimus and sirolimus) used in immunosuppression in transplant patients have alternatively been shown to contribute to AKI progression and tubular injury.⁴⁶ This suggests that *mTOR* may initially play a role in AKI pathogenesis but inhibition of the appropriate targets within the signaling pathway might prevent the progression of AKI to CKD. We also find that most mitochondrial genes are downregulated in COVID-19 patients with AKI. Mitochondrial oxidative phosphorylation pathways play a key role in the production of ATP and adaptive response to systemic inflammation, oxidative stress, and prevention of tubular injury.⁴⁷ Inhibition or downregulation of these pathways would likely contribute to maladaptive stress response and extended ischemia. Therapies targeting mitochondrial dysfunction, including pharmacological (SS-31,⁴⁸ mitoQ⁴⁹), cellular, and even mitochondrial transplantation, have potentially been considered for the treatment of ischemia-reperfusion injury. Given that mitochondrial dysfunction and downregulation of oxidative phosphorylation are key in mediating COVID-associated AKI⁵⁰ and CKD,⁵¹ one should consider repurposing therapies targeting mitochondria for the mitigation of kidney failure. In addition to inflammation and cellular stress responses/renal tubular injury, some of the molecular biomarkers have also previously been implicated in the worsening of renal damage in COVID-AKI patients. Specifically, genes such as *mir-21* and *HIF-1 alpha (HIF-1a)* have been known to play a significant role in the pathogenesis and progression of AKI to chronic renal disease. MicroRNAs are known to be critical in the activation of the innate immune system and the

Peripheral Transcriptomics in Acute and Long-Term Kidney Dysfunction in SARS-CoV2 Infection

regulation of the adaptive immune response.⁵² Mir-21 is a known regulator of apoptosis and involved in inflammatory and signaling pathways that may lead to hypoxia and tubular damage in patients with AKI.⁵² In another study, in PBMCs, mir-21 were shown to contribute to the underlying atherosclerosis by participating in the inflammatory processes governing angiogenesis in coronary artery disease.⁵³ HIF-1 alpha (HIF-1a or HIF1a) is also known as a master regulator of adaptive immune responses to hypoxia, a common condition in macrophage-driven inflammation due to a condition such as COVID-19.⁵⁴ In addition, HIF-1a and its alternate isoform, HIF-2a exert mutually antagonistic effects on the hypoxic states of the cell and the inflammatory pathways, which causes a reduction of Sirt-1 thus leading to chronic heart failure in the long term.⁵⁵ Furthermore, *EIF2* and *mTOR* pathways are also known to play a role in both autophagy and fibrosis, making them ideal therapeutic targets for the prevention of COVID-associated AKI progression or PASC.^{42,56} These instances of cardiorenal crosstalk play a common role in COVID-19 AKI and drive the progression to CKD in the long-term.⁵⁷

Previous studies have shown through histopathology and gene expression studies that there are significant similarities in the morphological and molecular profiles of patients with COVID-19-AKI and sepsis-associated AKI.^{58,12} In comparing our data from a pre-COVID-19 sepsis-associated AKI cohort,²⁵ we found that of the 55 reported pathways, 50% were common to both COVID-associated AKI and sepsis-associated AKI. The chief pathways that overlapped (**Supplementary Table 2C** and **Supplementary Figure 4A**) included pathways involved in inflammation, kidney injury, and mitochondrial response, namely 'T_{reg} signaling', 'ERK/MAPK signaling', 'IL-1 signaling', 'hypoxia signaling in the cardiovascular system', 'unfolded protein response', and 'RAR activation'. Pathways related to renal inflammation, tubular injury, and

Peripheral Transcriptomics in Acute and Long-Term Kidney Dysfunction in SARS-CoV2 Infection

oxidative phosphorylation were implicated in the pathogenesis of AKI and progression to CKD in both this transcriptomic analysis and in our previously published proteomic analyses.¹⁷ Our results indicate that therapies that target the immune system in sepsis-associated AKI could be of potential therapeutic advantage in COVID-AKI.

COVID-19 is associated with long-term kidney dysfunction, especially after AKI^{13,16}. Our analysis showed that 164 genes (**Table 2D-E**) from the 2635 DE genes implicated in the acute phase are associated with the overall trend of post-discharge progressive loss of renal function (**Table 2F**). We highlight the top 6 genes (ranked by strength of association and fold change) (**Figure 4**) as potential markers that may enable early risk stratification. Gene expression levels of *CALCOCO2*, *SIK3*, and *mir-29* were inversely correlated with overall trend of long-term eGFR, while gene expression levels of *KDM8*, and *MEF2C* were positively correlated with the overall trend of long-term eGFR. Calcium binding and coiled-coil domain-containing protein 2 (*CALCOCO2*, commonly known as *NDP52*) is an autophagy-related gene. In PBMCs interferon-signaling factor *tetherin* regulates mitophagy⁵⁹ via activation of *NDP52*. In patients with dilated cardiomyopathy, *NDP52* expression associated with autophagy-related reduced left ventricular function⁶⁰. *SIK3*, a regulator of pro-inflammatory cytokines such as TNF- α ,⁶¹ also polarizes macrophages leading to fibrosis and scarring^{35,61} in smooth muscle tissues.⁶² *Mir-29* is a master regulator of the adaptive immune system and contributes to the pathophysiology of CKD^{63,64} via a reno-protective effect.⁶⁵ In addition, *mir-29* plays a role in cardiac remodeling and hypertrophy⁶⁶ and is viewed as a potential biomarker for early detection and progression of CKD.⁶⁴ Loss of *MEF2C* in B-cells⁶⁷ causes defects in b-cell proliferation and survival via p38/MAPK pathway⁶⁸ and is prognostic of CKD progression in elderly patients.⁶⁹ *KDM8* (*JMJD5*), a critical regulator of DNA replication⁷⁰ under DNA damage

Peripheral Transcriptomics in Acute and Long-Term Kidney Dysfunction in SARS-CoV2 Infection

stress,⁷¹ is shown to epigenetically modulate cardiac metabolism via the p53/NFKB activation.⁷² In patients with diabetes, downregulation of *KDM8* was associated with the risk of dilated cardiomyopathy (DCM).⁷³ In addition, pathway overrepresentation analysis also highlighted the Actin-binding Rho activating (ABRA) signaling pathway (**Supplementary Table 2G**) in and the association of Rho GTPases with cardiac structure and function⁷⁴ and regulation of renal physiology and nephropathies.⁷⁵

A unique aspect of our study is the diversity of our patient cohort. The patient cohort for the COVID-19 AKI study also reflects the distribution of race and ethnicity⁷⁶ of the NYC catchment area.⁷⁷ The overall racial and ethnic distribution improves the generalizability and application of our findings to diverse populations.

It is important to interpret our results in the context of certain limitations. First, samples were collected during the hospital course of patients with confirmed COVID-19. However, logistical challenges during the pandemic resulted in the samples that were not collected at the exact same number of days post-hospitalization and were not standardized between patients. In addition, the time since the start of the SARS-CoV2 infection is unknown. This scenario is true across all COVID datasets and is not unique to ours. It is also important to note that while the samples were collected at multiple time points, our analysis was conducted using gene expression measurements from a single time point, after the patients had their last instance of AKI during hospitalization. Second, all patients enrolled in our study were collected in 2020, while our sepsis-associated AKI cohort was derived from a study in 2015 with different sample processing and library preparation methodologies before RNA-seq. While variability in processing strategies may reduce signal-to-noise when comparing the two cohorts, the different time periods of collection ensured that neither cohort has any confounding from

Peripheral Transcriptomics in Acute and Long-Term Kidney Dysfunction in SARS-CoV2 Infection

possible SARS-CoV2 infection/hospital-acquired SARS-CoV2 infections. Third, our current cohort was enrolled in the early pandemic between March-August of 2020. Given the large sample size of our study complicated by SARS-COV2 strain evolution via dynamic positive selection of mutations within the spike protein rather than mutations in the core,^{78,79} these results likely generalize across different variants. It would be remiss to not mention the subjective nature of interpretation of peripheral blood RNASeq results as a heterogeneous population can be affected by changes in the percentage of cell types. Future directions necessitate the need for single-cell RNASeq studies to disentangle these effects effectively and clearly.

In conclusion, we present a whole blood transcriptomic comparison of COVID-19 patients with and without AKI and long-term kidney dysfunction in the largest sample size to date. These results may have clinical utility in risk stratification of long-term kidney dysfunction after COVID-19 and for therapeutic repurposing.

Peripheral Transcriptomics in Acute and Long-Term Kidney Dysfunction in SARS-CoV2 Infection

DISCLOSURES

GNN and SGC report grants, personal fees, and non-financial support from Renalytix. GNN reports non-financial support from Pensieve Health, personal fees from AstraZeneca, personal fees from BioVie, personal fees from GLG Consulting, and personal fees from Siemens Healthineers from outside the submitted work. IP receives personal fees from Character Biosciences. ELT reports personal fees from Predigen and Biomeme and is currently employed by Danaher Diagnostics. None of the other authors have any other competing interests to declare.

FUNDING

This work was funded by R01DK127139 and R01DK127139-S1. This work was also supported in part through the computational resources and staff expertise provided by Scientific Computing at the Icahn School of Medicine at Mount Sinai and supported by the Clinical and Translational Science Awards (CTSA) grant UL1TR004419 from the National Center for Advancing Translational Sciences. The research reported in this paper additionally was supported by the Office of Research Infrastructure of the National Institutes of Health under award numbers S10OD026880 and S10OD030463. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

ACKNOWLEDGEMENTS.

We thank Wei Guo, Lili Gai, and Eugene Fluder of the High-Performance Computing group at 373 Mount Sinai for enabling the computational infrastructure underlying these experiments.

Peripheral Transcriptomics in Acute and Long-Term Kidney Dysfunction in SARS-CoV2 Infection

AUTHOR CONTRIBUTIONS.

Conceptualization: GNN, PJ, IP.

Methodology: PJ, IP, LL, RT, NB, MSF, GVR, SD, SKS, EK.

Investigation: PJ, IP, RT, DMDV, GVR, SD, EGK, FG, JK, AC.

Visualization: PJ, IP, MSF, WO, JK, RT, EGK, AV, AC.

Funding acquisition: GNN, SGC, JCH.

Supervision: GNN, AWC, NB, RT, NB, SGC, LC, JCH.

Writing: PJ, IP, MR, GNN.

Revisions: PJ, MR, ET, RLL, MSF, RT, LC, SD, JJ, FG, GNN.

Peripheral Transcriptomics in Acute and Long-Term Kidney Dysfunction in SARS-CoV2 Infection

DATA SHARING STATEMENT

Data Availability

This research was reviewed and approved by the Icahn School of Medicine at Mount Sinai Program for the Protection of Human Subjects (PPHS) under study number 20–00341. The clinical data tables and analysis data are available in the Synapse repository syn35874390. Synapse can be accessed at <https://www.synapse.org/#!/Synapse:syn35874390>.

Code Availability

The code is available at our GitHub repository **Nadkarni-Lab: aki_covid_transcriptomics** here: https://github.com/Nadkarni-Lab/aki_covid_transcriptomics.

Peripheral Transcriptomics in Acute and Long-Term Kidney Dysfunction in SARS-CoV2 Infection

REFERENCES

1. Chan, L., *et al.* AKI in hospitalized patients with COVID-19. *Journal of the American Society of Nephrology* **32**, 151-160 (2021).
2. Legrand, M., *et al.* Pathophysiology of COVID-19-associated acute kidney injury. *Nat Rev Nephrol* **17**, 751-764 (2021).
3. Fisher, M., *et al.* AKI in Hospitalized Patients with and without COVID-19: A Comparison Study. *J Am Soc Nephrol* **31**, 2145-2157 (2020).
4. Gameiro, J., *et al.* Acute kidney injury in hospitalized patients with COVID-19: A Portuguese cohort. *Nefrologia (Engl Ed)* **41**, 689-698 (2021).
5. Ounci, E., *et al.* Acute kidney injury in critically ill patients with COVID-19: prevalence, risk factors and mortality in eastern Morocco. *J Nephrol* **35**, 2383-2386 (2022).
6. Dellepiane, S., *et al.* Acute Kidney Injury in Patients Hospitalized With COVID-19 in New York City: Temporal Trends From March 2020 to April 2021. *Kidney Med* **3**, 877-879 (2021).
7. Kes, P. & Basic Jukic, N. Acute kidney injury in the intensive care unit. *Bosn J Basic Med Sci* **10 Suppl 1**, S8-12 (2010).
8. Ahmadian, E., *et al.* Covid-19 and kidney injury: Pathophysiology and molecular mechanisms. *Rev Med Virol* **31**, e2176 (2021).
9. Santoriello, D., *et al.* Postmortem Kidney Pathology Findings in Patients with COVID-19. *J Am Soc Nephrol* **31**, 2158-2167 (2020).
10. Golmai, P., *et al.* Histopathologic and Ultrastructural Findings in Postmortem Kidney Biopsy Material in 12 Patients with AKI and COVID-19. *J Am Soc Nephrol* **31**, 1944-1947 (2020).
11. Gomez, H., *et al.* A unified theory of sepsis-induced acute kidney injury: inflammation, microcirculatory dysfunction, bioenergetics, and the tubular cell adaptation to injury. *Shock* **41**, 3-11 (2014).
12. Alexander, M.P., *et al.* Acute Kidney Injury in Severe COVID-19 Has Similarities to Sepsis-Associated Kidney Injury: A Multi-Omics Study. *Mayo Clin Proc* **96**, 2561-2575 (2021).
13. Bowe, B., Xie, Y., Xu, E. & Al-Aly, Z. Kidney Outcomes in Long COVID. *J Am Soc Nephrol* **32**, 2851-2862 (2021).
14. Thompson, R.C., *et al.* Molecular states during acute COVID-19 reveal distinct etiologies of long-term sequelae. *Nat Med* **29**, 236-246 (2023).
15. Al-Aly, Z., Xie, Y. & Bowe, B. High-dimensional characterization of post-acute sequelae of COVID-19. *Nature* **594**, 259-264 (2021).
16. Su, Y., *et al.* Multiple early factors anticipate post-acute COVID-19 sequelae. *Cell* **185**, 881-895 e820 (2022).
17. Paranjpe, I., *et al.* Proteomic characterization of acute kidney injury in patients hospitalized with SARS-CoV2 infection. *Commun Med (Lond)* **3**, 81 (2023).
18. Charney, A.W., *et al.* Sampling the host response to SARS-CoV-2 in hospitals under siege. *Nat Med* **26**, 1157-1158 (2020).
19. Del Valle, D.M., *et al.* An inflammatory cytokine signature predicts COVID-19 severity and survival. *Nat Med* **26**, 1636-1643 (2020).
20. Khwaja, A. KDIGO clinical practice guidelines for acute kidney injury. *Nephron Clin Pract* **120**, c179-184 (2012).
21. Kellum, J.A., *et al.* Kidney disease: improving global outcomes (KDIGO) acute kidney injury work group. KDIGO clinical practice guideline for acute kidney injury. *Kidney international supplements* **2**, 1-138 %@ 2157-1724 (2012).
22. Zavada, J., *et al.* A comparison of three methods to estimate baseline creatinine for RIFLE classification. *Nephrol Dial Transplant* **25**, 3911-3918 (2010).
23. Ritchie, M.E., *et al.* limma powers differential expression analyses for RNA-sequencing and microarray studies. *Nucleic Acids Res* **43**, e47 (2015).
24. Hoffman, G.E. & Schadt, E.E. variancePartition: interpreting drivers of variation in complex gene expression studies. *BMC Bioinformatics* **17**, 483 (2016).
25. Tsalik, E.L., *et al.* Renal systems biology of patients with systemic inflammatory response syndrome. *Kidney Int* **88**, 804-814 (2015).

Peripheral Transcriptomics in Acute and Long-Term Kidney Dysfunction in SARS-CoV2 Infection

26. Love, M.I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol* **15**, 550 (2014).
27. Levey, A.S., *et al.* A new equation to estimate glomerular filtration rate. *Ann Intern Med* **150**, 604-612 (2009).
28. Kuznetsova, A., Brockhoff, P.B. & Christensen, R.H.B. lmerTest Package: Tests in Linear Mixed Effects Models. *J Stat Softw* **82**, 1-26 (2017).
29. Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. *Journal of the Royal statistical society: series B (Methodological)* **57**, 289-300 (1995).
30. Vincent, J.L., *et al.* Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on "sepsis-related problems" of the European Society of Intensive Care Medicine. *Crit Care Med* **26**, 1793-1800 (1998).
31. Jain, S., *et al.* RNASeq profiling of COVID19-infected patients identified an EIF2AK2 inhibitor as a potent SARS-CoV-2 antiviral. *Clin Transl Med* **12**, e1098 (2022).
32. van der Slikke, E.C., *et al.* Sepsis is associated with mitochondrial DNA damage and a reduced mitochondrial mass in the kidney of patients with sepsis-AKI. *Crit Care* **25**, 36 (2021).
33. Alobaidi, R., Basu, R.K., Goldstein, S.L. & Bagshaw, S.M. Sepsis-associated acute kidney injury. *Semin Nephrol* **35**, 2-11 (2015).
34. Ferre, S., *et al.* Renal tubular cell spliced X-box binding protein 1 (Xbp1s) has a unique role in sepsis-induced acute kidney injury and inflammation. *Kidney Int* **96**, 1359-1373 (2019).
35. Cantero-Navarro, E., *et al.* Role of Macrophages and Related Cytokines in Kidney Disease. *Front Med (Lausanne)* **8**, 688060 (2021).
36. Li, P., *et al.* Mitochondrial respiratory dysfunctions of blood mononuclear cells link with cardiac disturbance in patients with early-stage heart failure. *Sci Rep* **5**, 10229 (2015).
37. Czajka, A., *et al.* Altered Mitochondrial Function, Mitochondrial DNA and Reduced Metabolic Flexibility in Patients With Diabetic Nephropathy. *EBioMedicine* **2**, 499-512 (2015).
38. Altintas, M.M., DiBartolo, S., Tadros, L., Samelko, B. & Wasse, H. Metabolic Changes in Peripheral Blood Mononuclear Cells Isolated From Patients With End Stage Renal Disease. *Front Endocrinol (Lausanne)* **12**, 629239 (2021).
39. Moore, D.F., *et al.* Using peripheral blood mononuclear cells to determine a gene expression profile of acute ischemic stroke: a pilot investigation. *Circulation* **111**, 212-221 (2005).
40. Versteeg, G.A., van de Nes, P.S., Bredenbeek, P.J. & Spaan, W.J. The coronavirus spike protein induces endoplasmic reticulum stress and upregulation of intracellular chemokine mRNA concentrations. *J Virol* **81**, 10981-10990 (2007).
41. Yan, M., Shu, S., Guo, C., Tang, C. & Dong, Z. Endoplasmic reticulum stress in ischemic and nephrotoxic acute kidney injury. *Ann Med* **50**, 381-390 (2018).
42. Shrestha, N., *et al.* Eukaryotic initiation factor 2 (eIF2) signaling regulates proinflammatory cytokine expression and bacterial invasion. *J Biol Chem* **287**, 28738-28744 (2012).
43. Dong, G., *et al.* mTOR contributes to ER stress and associated apoptosis in renal tubular cells. *Am J Physiol Renal Physiol* **308**, F267-274 (2015).
44. Wang, Y., *et al.* AMPK/mTOR Signaling in Autophagy Regulation During Cisplatin-Induced Acute Kidney Injury. *Front Physiol* **11**, 619730 (2020).
45. Su, Y., *et al.* Rapamycin induces autophagy to alleviate acute kidney injury following cerebral ischemia and reperfusion via the mTORC1/ATG13/ULK1 signaling pathway. *Mol Med Rep* **18**, 5445-5454 (2018).
46. Ma, M.K.M., Yung, S. & Chan, T.M. mTOR Inhibition and Kidney Diseases. *Transplantation* **102**, S32-S40 (2018).
47. Yuan, Y., *et al.* The roles of oxidative stress, endoplasmic reticulum stress, and autophagy in aldosterone/mineralocorticoid receptor-induced podocyte injury. *Lab Invest* **95**, 1374-1386 (2015).
48. Zhu, Y., *et al.* SS-31, a Mitochondria-Targeting Peptide, Ameliorates Kidney Disease. *Oxid Med Cell Longev* **2022**, 1295509 (2022).
49. Gottwald, E.M., *et al.* The targeted anti-oxidant MitoQ causes mitochondrial swelling and depolarization in kidney tissue. *Physiol Rep* **6**, e13667 (2018).
50. Clark, A.J. & Parikh, S.M. Mitochondrial Metabolism in Acute Kidney Injury. *Semin Nephrol* **40**, 101-113 (2020).
51. Jiang, M., *et al.* Mitochondrial dysfunction and the AKI-to-CKD transition. *Am J Physiol Renal Physiol* **319**, F1105-F1116 (2020).

Peripheral Transcriptomics in Acute and Long-Term Kidney Dysfunction in SARS-CoV2 Infection

52. Chafin, C.B. & Reilly, C.M. MicroRNAs implicated in the immunopathogenesis of lupus nephritis. *Clin Dev Immunol* **2013**, 430239 (2013).
53. Nariman-Saleh-Fam, Z., *et al.* Expression pattern of miR-21, miR-25 and PTEN in peripheral blood mononuclear cells of patients with significant or insignificant coronary stenosis. *Gene* **698**, 170-178 (2019).
54. Li, Z.L., *et al.* HIF-1alpha is transcriptionally regulated by NF-kappaB in acute kidney injury. *Am J Physiol Renal Physiol* **321**, F225-F235 (2021).
55. Packer, M. Mutual Antagonism of Hypoxia-Inducible Factor Isoforms in Cardiac, Vascular, and Renal Disorders. *JACC Basic Transl Sci* **5**, 961-968 (2020).
56. Wang, J., *et al.* Attenuation of mTOR Signaling Is the Major Response Element in the Rescue Pathway of Chronic Kidney Disease in Rats. *Neuroimmunomodulation* **27**, 9-18 (2020).
57. Huang, C.K., Bar, C. & Thum, T. miR-21, Mediator, and Potential Therapeutic Target in the Cardiorenal Syndrome. *Front Pharmacol* **11**, 726 (2020).
58. Kellum, J.A., Nadim, M.K. & Forni, L.G. Sepsis-associated acute kidney injury: is COVID-19 different? *Kidney Int* **98**, 1370-1372 (2020).
59. Bhatia, D. & Choi, M.E. The Emerging Role of Mitophagy in Kidney Diseases. *J Life Sci (Westlake Village)* **1**, 13-22 (2019).
60. Gil-Cayuela, C., *et al.* The altered expression of autophagy-related genes participates in heart failure: NRBP2 and CALCOCO2 are associated with left ventricular dysfunction parameters in human dilated cardiomyopathy. *PLoS One* **14**, e0215818 (2019).
61. Darling, N.J., Toth, R., Arthur, J.S. & Clark, K. Inhibition of SIK2 and SIK3 during differentiation enhances the anti-inflammatory phenotype of macrophages. *Biochem J* **474**, 521-537 (2017).
62. Cai, Y., *et al.* Salt-Inducible Kinase 3 Promotes Vascular Smooth Muscle Cell Proliferation and Arterial Restenosis by Regulating AKT and PKA-CREB Signaling. *Arterioscler Thromb Vasc Biol* **41**, 2431-2451 (2021).
63. Liston, A., Papadopoulou, A.S., Danso-Abeam, D. & Dooley, J. MicroRNA-29 in the adaptive immune system: setting the threshold. *Cell Mol Life Sci* **69**, 3533-3541 (2012).
64. Motshwari, D.D., *et al.* MicroRNAs Associated with Chronic Kidney Disease in the General Population and High-Risk Subgroups-A Systematic Review. *Int J Mol Sci* **24**(2023).
65. Kriegel, A.J., Liu, Y., Fang, Y., Ding, X. & Liang, M. The miR-29 family: genomics, cell biology, and relevance to renal and cardiovascular injury. *Physiol Genomics* **44**, 237-244 (2012).
66. Sassi, Y., *et al.* Cardiac myocyte miR-29 promotes pathological remodeling of the heart by activating Wnt signaling. *Nat Commun* **8**, 1614 (2017).
67. Wilker, P.R., *et al.* Transcription factor Mef2c is required for B cell proliferation and survival after antigen receptor stimulation. *Nat Immunol* **9**, 603-612 (2008).
68. Khiem, D., Cyster, J.G., Schwarz, J.J. & Black, B.L. A p38 MAPK-MEF2C pathway regulates B-cell proliferation. *Proc Natl Acad Sci U S A* **105**, 17067-17072 (2008).
69. Lin, J., Tang, B., Feng, Z., Hao, W. & Hu, W. Decreased B lymphocytes subpopulations are associated with higher atherosclerotic risk in elderly patients with moderate-to-severe chronic kidney diseases. *BMC Nephrol* **22**, 396 (2021).
70. Fletcher, S.C., *et al.* Impaired protein hydroxylase activity causes replication stress and developmental abnormalities in humans. *J Clin Invest* **133**(2023).
71. Shen, J., *et al.* JMJD5 cleaves monomethylated histone H3 N-tail under DNA damaging stress. *EMBO Rep* **18**, 2131-2143 (2017).
72. Keating, S.T., Plutzky, J. & El-Osta, A. Epigenetic Changes in Diabetes and Cardiovascular Risk. *Circ Res* **118**, 1706-1722 (2016).
73. Ahmed, A., *et al.* KDM8 epigenetically controls cardiac metabolism to prevent initiation of dilated cardiomyopathy. *Nature Cardiovascular Research* **2**, 174-191 (2023).
74. Troidl, K., *et al.* Actin-binding rho activating protein (Abra) is essential for fluid shear stress-induced arteriogenesis. *Arterioscler Thromb Vasc Biol* **29**, 2093-2101 (2009).
75. Steichen, C., Herve, C., Hauet, T. & Bourmeyster, N. Rho GTPases in kidney physiology and diseases. *Small GTPases* **13**, 141-161 (2022).
76. Eskandari, A., *et al.* Retrospective analysis of demographic factors in COVID-19 patients entering the Mount Sinai Health System. *PLoS One* **16**, e0254707 (2021).
77. Wang, Z., *et al.* Hospitalised COVID-19 patients of the Mount Sinai Health System: a retrospective observational study using the electronic medical records. *BMJ Open* **10**, e040441 (2020).

Peripheral Transcriptomics in Acute and Long-Term Kidney Dysfunction in SARS-CoV2 Infection

78. Harvey, W.T., *et al.* SARS-CoV-2 variants, spike mutations and immune escape. *Nat Rev Microbiol* **19**, 409-424 (2021).
79. Braet, S.M., *et al.* Timeline of changes in spike conformational dynamics in emergent SARS-CoV-2 variants reveal progressive stabilization of trimer stalk with altered NTD dynamics. *Elife* **12**(2023).

Peripheral Transcriptomics in Acute and Long-Term Kidney Dysfunction in SARS-CoV2 Infection

Table 1A Summary statistics for the COVID-AKI cohort.

Cohort Characteristics	Developed AKI (Stage 1/2/3) during hospitalization	No AKI during hospitalization	p-value
	N=106	N=177	
Age, mean (SD)	66.5 (15.4)	61.4 (16.6)	0.01409
Male, n (%)	63 (59%)	99 (56%)	0.62006
Race, n (%)			
White	38(36%)	57 (32%)	
Black or African American	22 (21%)	43 (24%)	
Other	46 (42%)	77 (44%)	
Ethnicity, n (%)			
Hispanic or Latino	50 (47%)	62 (35%)	0.03523
Not Hispanic or Latino	55 (53%)	110 (62%)	0.03523
Unknown / Not Reported	1 (0%)	5 (3%)	
Vitals & Lab Parameters during Hospitalization, n (SD)			
SOFA	5.79 (4.35)	1.2 (1.65)	<0.001
Modified SOFA	4.56 (4.03)	1.09 (1.52)	<0.001
Baseline Creatinine (mg/dL)	1.07 (0.592)	0.929 (0.27)	0.34942
Maximum Lactate (mmol/L)	1.88 (1.32)	1.3 (0.43)	0.35154
Minimum Systolic Blood Pressure (mmHg)	106 (17.2)	111 (13)	0.00409
Maximum Systolic Blood Pressure (mmHg)	142 (20.9)	137 (20.5)	0.02945
Maximum Pulse (bpm)	103 (18.5)	90.5 (17.9)	<0.001
Maximum Blood Urea Nitrogen (mmol/L)	52.2 (34.6)	16.9 (10.4)	<0.001
Maximum White Blood Cell Count (10 ⁹ /L)	12.8 (7.19)	7.8 (3.46)	<0.001
Minimum Platelet Count (10 ⁹ /L)	270 (144)	318 (140)	0.00664
Minimum Lymphocyte count (10 ⁹ /L)	2.03 (3.17)	2.31 (3.71)	0.00862
Maximum Creatinine (mg/dL)	2.71 (2.6)	0.862 (0.365)	<0.001
Maximum Ferritin (ug/L)	1650 (2140)	932 (1240)	0.02712
Maximum IL1-β (pg/mL)	0.4 (NA)	0.6 (0.216)	0.46816
Comorbidities, n (%)			
Atrial Fibrillation	21 (20%)	17 (10%)	0.01893
Coronary Artery Disease	19 (18%)	26 (15%)	0.50390
Arterial Hypertension	48 (45%)	71 (40%)	0.45556
Diabetes	39 (37%)	32 (18%)	0.00063
Chronic Kidney Disease	21 (20%)	8 (5%)	<0.001

Peripheral Transcriptomics in Acute and Long-Term Kidney Dysfunction in SARS-CoV2 Infection

Highest Respiratory support n(%)			
Intubation	49 (46%)	9 (5%)	<0.001
Non-Invasive Ventilation	9 (8%)	8 (5%)	0.20040
Nasal Cannula	34 (32%)	91 (51%)	0.00194
No Ventilation	14 (13%)	69 (39%)	<0.001
Vasopressor Use during Hospitalization n (%)			
Any vasopressor	55 (52%)	12 (7%)	<0.001
Norepinephrine	49 (46%)	10 (6%)	<0.001
Vasopressin	18 (17%)	2 (1%)	<0.001
Phenylephrine	15 (14%)	1 (1%)	<0.001
Epinephrine	3 (3%)	2 (1%)	0.36667
Milrinone	3 (3%)	1 (1%)	0.14950
Dopamine	1 (1%)	0 (0%)	0.37456

Table 1B Patient cohort summary statistics for the post-discharge follow-up cohort for long-term eGFR analysis.

Cohort Characteristics	Developed AKI (Stage 1/2/3) during hospitalization	No AKI during hospitalization	p-value	Total (Category %)
	N=31	N=84		115
Age, mean (SD)	60 (15.9)	59 (15.76)		
Male, n (%)	16 (52%)	44 (52.3%)		60 (52.17%)
Race, n (%)				
White	7(22.5%)	21 (25%)		28 (24.34%)
Black or African American	7 (22.5%)	25 (29.76%)		32 (27.82%)
Other	17 (54.83%)	38 (45.23%)		55 (47.82%)
Ethnicity, n (%)				
Hispanic or Latino	14 (45.16%)	27 (32.14%)		41 (35.65%)
Not Hispanic or Latino	16 (51.61%)	50 (59.52%)		66 (57.39%)
Unknown / Not Reported	1 (0%)	7 (1%)		8 (7%)
Vitals & Lab Parameters During Hospitalization, n				

Peripheral Transcriptomics in Acute and Long-Term Kidney Dysfunction in SARS-CoV2 Infection

(SD)				
SOFA	3.84 (2.72)	1.17 (1.82)	p < 0.001	
Modified SOFA	2.84 (2.78)	1.05 (1.66)	p < 0.001	
Baseline Creatinine (mg/dL)	1.17 (0.6)	0.968 (0.211)		
Maximum Lactate (mmol/L)	1.65 (1.19)	1.7 (0.283)		
Minimum Systolic Blood Pressure (mmHg)	109 (16.4)	112 (12.9)		
Maximum Systolic Blood Pressure (mmHg)	137 (17.2)	138 (20.8)		
Maximum Pulse (bpm)	98.8 (16.3)	89.5 (14.2)	p = 0.0023	
Maximum Blood Urea Nitrogen (mmol/L)	41.9 (28.2)	16.3 (9.41)	p < 0.001	
Maximum White Blood Cell count (10 ⁹ /L)	9.46 (5.16)	7.62 (3.25)		
Minimum Platelet count (10 ⁹ /L)	252 (150)	328 (151)	p = 0.00823	
Minimum Lymphocyte count (10 ⁹ /L)	2.97 (4.06)	2.59 (4.45)		
Maximum Creatinine (mg/dL)	2.27 (2.11)	0.894 (0.408)	p < 0.001	
Maximum Ferritin (ug/L)	1900 (2810)	981 (1380)		
Maximum IL-1β (pg/mL)	0.4 (NA)	0.7 (0.283)		
Comorbidities, n (%)				
Atrial Fibrillation	8 (26%)	11 (13%)		19 (16.52%)
Coronary Artery Disease	8 (26%)	13 (15%)		21 (18.26%)
Arterial Hypertension	15 (48%)	40 (48%)		55 (47.82%)
Diabetes	14 (45%)	21 (25%)	p = 0.043	35 (30.43%)
Chronic Kidney Disease	8 (26%)	5 (6%)	p = 0.00587	13 (11.3%)
Vasopressor use during hospitalization. n (%)				
Any Vasopressor	15 (48%)	7 (8%)	p < 0.001	22 (19.13%)
Norepinephrine	12 (39%)	6 (7%)	p < 0.001	28 (24.34%)
Vasopressin	7 (23%)	1 (1%)	p < 0.001	8 (7%)
Phenylephrine	2 (6%)	1 (1%)		3 (3%)
Epinephrine	0 (0%)	2 (2%)		2 (1.7%)
Milrinone	2 (6%)	1 (1%)		3 (3%)

Peripheral Transcriptomics in Acute and Long-Term Kidney Dysfunction in SARS-CoV2 Infection

Table 1C Additional summary statistics for the long-term eGFR patient cohort in **Table 1B**.

Cohort features	Min	Max	Median	Mean	SD
Age	20	90	62	59	15.75
Number of eGFR Measurements	1	58	4	10	169
Mean eGFR Values	4.5	140.22	76.41	74.93	29.51
eGFR Measurement	0.0258	2014.68	46.62	157.7	
Least Number of Days between Discharge and Follow-Up eGFR Measurement	1	520	34	78.83	33
Highest Number of Days between Discharge and Follow-Up eGFR Measurement	13	536	375	326.1	30

FIGURE TITLES and LEGENDS

Figure 1a. Flowchart of patients included in the current study.

Figure 1b. Timeline of sample collection for current study

Figure 1 Legend. Figure 1a shows the patients and samples included in the current study, and Figure 1b shows a visualization of the sample collection timeline.

Figure 2a. Heatmap showing the differential expression of 2635 genes between cases (COVID-AKI) and controls (COVID with no AKI).

Figure 2b. Volcano plot of the differentially expressed genes showing large numbers of significantly downregulated mitochondrial toxicity and endoplasmic reticulum genes.

Figure 3a. Canonical pathways identified in IPA during the functional characterization of the differentially expressed genes. The top pathways resulting from the analysis include *EiF2* signaling, *eIF4/p70S6K* signaling, oxidative phosphorylation and mitochondrial dysfunction.

Figure. 3b. Curated list from Ingenuity Pathway Analysis

Figure 3 Legend. Figure 3b shows a majority of downregulated genes in ‘mitochondrial dysfunction’ and ‘*NF-KB* signaling’. Additionally large number of upregulated genes are involved in the pathways involved in ‘cardiac hypertrophy’, ‘increased renal dysfunction’ (PPAR α activation) and damage.

Figure 4. Association of differentially expressed gene signatures in AKI in the COVID-AKI cohort and overall decline in eGFR in the long-term cohort 1-year post-discharge.

Figure 4 Legend. Figure 4 shows a plot of the expression of 2635 genes associated with AKI in the COVID-AKI cohort against the β estimates of the linear mixed model that analyzes the effect of these expressions over the long-term decline of eGFR. The gene

expressions are plotted by fold change on the x-axis (\log_2 fold change). The y-axis is the beta estimate of the overall change in long-term eGFR from the linear mixed model analysis. A negative beta(β) estimate for overall change in long-term eGFR, signals that genes that show a higher positive expression are negatively correlated with overall decrease in post-discharge eGFR while genes with a higher negative expression are directly correlated with overall decrease in post-discharge eGFR.

Fig 1.A.

Mount Sinai COVID-AKI Cohort




Fig 1.B.




Fig 2.A.




Fig 2.B.




Fig 3.




Fig 5.

